7-OH Clinical Intake & Withdrawal Management Protocol

A Structured Framework for Triage, Risk Stratification, and Treatment Matching

1. Clinical & Pharmacological Context

7-hydroxymitragynine (7-OH) is a highly potent, short-acting, semi-synthetic opioid-active alkaloid synthetically modified from mitragynine, the primary alkaloid in kratom leaves. While 7-OH comprises only 2% of the total alkaloid content in raw kratom, modern retail markets have seen a rapid proliferation of purified, concentrated products (e.g., pressed tablets, liquid shots, gummies, and films) marketed deceptively as 'natural botanical supplements'. 7-OH functions as a potent mu-opioid receptor (MOR) agonist with exceptionally high receptor affinity and potency. Preclinical data show that 7-OH is about 100 times more potent than mitragynine at the MOR, and is significantly more potent than morphine. This strong opioid-like pharmacological profile drives rapid physiological dependence, tolerance, severe addiction, and severe withdrawal symptoms. Chronic use is associated with high cardiotoxicity, hepatic and renal toxicity, seizures, and fatal respiratory depression. Crucially, standard Clinical Opiate Withdrawal Scale (COWS) scores can under-read or underestimate the severe subjective distress and neuropsychiatric symptoms of 7-OH withdrawal, as concentrated products can also carry significant stimulant, adrenergic, serotonergic, and atypical receptor effects. Clinicians must recognize this as a highly addictive de facto opioid syndrome requiring specialized medication-assisted treatment (MAT) protocols.

2. Structured Five-Step Clinical Intake Algorithm

Clinicians should utilize this systematic triage process to define the patient's exposure, assess physiological dependence, stratify medical risk, and choose the safest clinical pathway.

- **Step 1: Define Exposure:** Screen and record the specific 7-OH formulation used (chewable pressed tablets, flavored liquid extracts/shots, gummies, sublingual films, or raw powders). Quantify the labeled milligrams of 7-OH consumed daily, actual frequency of administration, and redosing interval (heavy users frequently report hourly or highly frequent dosing to prevent interdose withdrawal). Document the duration of use (months/years) and the patient's daily financial expenditure.
- **Step 2: Determine Dependence Severity:** Assess the onset and severity of interdose withdrawal symptoms and failed self-cessation attempts (often aborted due to intense physical cravings). Screen for functional impairment in daily activities, compulsive use patterns, and standard DSM-5 diagnostic criteria for severe Opioid Use Disorder (OUD).
- **Step 3: Risk Stratify:** Identify patients carrying high-risk clinical profiles that require specialized medical supervision. Higher-risk individuals include: patients taking exceptionally high daily doses (e.g., 30 mg to 50 mg of 7-OH daily) or redosing hourly; individuals with underlying seizure disorders, cardiac disease, autonomic instability, frailty, or pregnancy; older/younger age; unstable psychiatric conditions; polysubstance use (such as co-exposure to alcohol, benzodiazepines, stimulants, fentanyl, gabapentinoids, or nicotine); and those taking medications that complicate buprenorphine initiation, escalate sedation risk, or interact with CYP450 drug metabolism pathways.
- **Step 4: Match Treatment Setting:** Assign patients to appropriate levels of care based on risk stratification. Options span outpatient structured tapers with clinical support, outpatient buprenorphine/naloxone (Suboxone) induction, inpatient low-dose buprenorphine initiation (microinduction) for severe high-dose cases, or transfer to high-level medically managed inpatient detox centers (ASAM Level 4).
- **Step 5: Prevent Substitution & Safety Planning:** Establish a definitive safety plan before retail access shifts due to impending DEA scheduling. Provide explicit warnings regarding the high risk of fatal illicit substitution (e.g., patients panicking and turning to street fentanyl or heroin to stop severe withdrawal). Co-prescribe a naloxone rescue kit, schedule a tight follow-up clinical interval, and integrate close family or caregiver monitoring whenever appropriate.

REGULATORY TRANSITION & IMPLEMENTATION ALERT

Under the Drug Enforcement Administration (DEA) Notice of Intent, qualifying concentrated 7-OH products containing a dry-weight concentration above 0.05% or over 1.00 mg per article will temporarily be placed into Schedule I of the Controlled Substances Act, effective immediately upon formal Federal Register publication. Once active, this scheduling will make the manufacture, distribution, and possession of covered 7-OH retail products a federal crime. Clinicians must expect a sudden wave of patients experiencing acute withdrawal who are at extreme risk of illicit opioid substitution if safe medical bridges are not established.

7-OH Clinical Intake & Withdrawal Management Protocol

3. Standard Clinician Screening Questionnaire

Clinicians should ask these questions directly during initial triage. Patients often view these products as natural 'herbal supplements' rather than opioids and may not volunteer use unless prompted specifically.

1. **Specific Product Identification:** 'Do you use kratom, 7-OH, 7-hydroxy, shots, tablets, films, or gummies from smoke shops, gas stations, or online? Do you recognize brand names like Press'd, 7OHMZ, Hydroxie, Kama, Happie Tabs, or Fruity Perks?'
2. **Dosing Profile:** 'How many tablets or shots do you use per day, what is the labeled milligram strength, how often do you take a dose, and how much are you spending daily on these products?'
3. **Withdrawal Onset:** 'How soon after a dose do you begin to experience withdrawal symptoms (such as severe physical restlessness, chills, anxiety, sweating, or heart racing)?'
4. **Cessation History:** 'Have you ever tried to cut down or stop? What symptoms or cravings caused the attempt to fail?'
5. **Co-Exposures:** 'Do you regularly consume other substances, such as alcohol, benzodiazepines, pain pills, stimulants, gabapentin, or daily vape nicotine products?'
6. **Substitution Risk:** 'If your regular 7-OH product became completely unavailable tomorrow, would you consider using street drugs, non-prescribed pain pills, or fentanyl to manage the withdrawal pain?'
7. **Overdose Safety:** 'Do you currently have a naloxone rescue kit at home, and does anyone near you know how to identify an overdose and administer the spray?'

4. 7-OH Clinical Withdrawal Timeline

Timeframe	Clinical Presentation & Key Symptoms
0 – 8 Hours	**Interdose Withdrawal (Onset):** Early symptoms emerge in heavy users. Marked by rising anxiety, severe physical restlessness, yawning, sweating, chills, muscle tension, and initial gastrointestinal (GI) hypermotility.
8 – 16 Hours	**Active Phase:** Clear and unmistakable physical signs develop. Marked by pronounced insomnia, severe hot/cold chills, full-body muscle aches (myalgias), abdominal cramping, nausea, mild tremors, and tachycardia.
16 – 36 Hours	**Peak Autonomic Phase:** Severe physiological distress. Intense vomiting, persistent diarrhea, severe abdominal spasms, heavy sweating, pronounced tremors, tachycardia (fast heartbeat), and profound dysphoria.
Days 2 – 3	**Peak Acute Phase:** Often the absolute roughest physical and psychological window. Marked by complete insomnia, severe muscle cramps/spasms, overwhelming anxiety, agitation, and high risk of dehydration.
Days 3 – 5	**Autonomic Resolution:** Severe physical symptoms slowly begin to ease. Autonomic distress and gastrointestinal hypermotility decrease, but sleep remains highly fragmented, and extreme fatigue is common.
Day 5 – 14+	**Protracted Phase:** Acute physical syndrome largely resolves. However, severe psychological symptoms—including protracted insomnia, deep dysphoria, anhedonia, severe anxiety, and intense cravings—can persist for weeks.

5. Medication-Assisted Treatment (MAT) Dosing Guidance

MAT DOSING & INITIATION PROTOCOLS

Standard Buprenorphine Induction: Clinicians must NEVER initiate standard buprenorphine by the clock alone. Traditional induction should only begin once the patient is in clear, objective physical withdrawal (COWS score > 12 with visible signs of mydriasis, rhinorrhea, or piloerection). Initiating a standard dose of buprenorphine too early (less than 16–24 hours after last 7-OH use) carries a moderate-to-high risk of **precipitated withdrawal** due to buprenorphine's partial mu-opioid receptor agonism and extremely high affinity. Standard Day 1 dosing can utilize 2 mg sublingual (SL) buprenorphine PRN once objective criteria are fully met, titrated to comfort.

Low-Dose Buprenorphine Microinduction (Tapered Cross-Over): For highly dependent patients consuming severe daily doses (such as 30 mg to 50 mg/day) or those with severe anxiety or a history of failed quit attempts, a low-dose buprenorphine microinduction is strongly indicated. Over multiple days, the patient is started on micro-doses of buprenorphine (e.g., via a low-dose transdermal buprenorphine patch or very small sublingual fractions) while they continue taking 7-OH. This gradually occupies mu-opioid receptors without displacing 7-OH abruptly, bypassing the distressed waiting window entirely. Titrate buprenorphine incrementally to an OUD stabilization target (typically 12 mg daily), at which point the 7-OH is discontinued, and maintenance buprenorphine-naloxone (Suboxone) therapy is established successfully.